1 – 8 of 8
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2002
-
Mark
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer
(
- Contribution to journal › Article
-
Mark
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
(
- Contribution to journal › Article
-
Mark
Physical performance, toxicity, and quality of life as assessed by the physician and the patient
(
- Contribution to journal › Article
- 2001
-
Mark
Timing of quality of life (QoL) assessments as a source of error in oncological trials
(
- Contribution to journal › Article
- 2000
-
Mark
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
(
- Contribution to journal › Article
-
Mark
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
(
- Contribution to journal › Article
- 1999
-
Mark
Predictive value of P53, MDM-2, P21-expression, KI-67 for response to docetaxel or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Predictive value c-erB-B2 expression for response to docetaxel (D) or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract